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Eﬀects of olopatadine hydrochloride, a histamine H1 receptor antagonist, on histamine-induced skin responses were evaluated in
10 healthy subjects in comparison with placebo, fexofenadine hydrochloride, and bepotastine besilate. Olopatadine signiﬁcantly
suppressed histamine-induced wheal, ﬂare, and itch, starting 30 minutes after oral administration. Olopatadine was more eﬀective
than fexofenadine and bepotastine. None of the drugs studied impaired performance of word processing tasks. These results
suggest that olopatadine can suppress skin symptoms caused by histamine soon after administration.
1.Introduction
Urticaria is a skin disease which is induced by chemical
mediators,mainlyhistamine,releasedfromskinmastcellsby
some stimulation. These chemical mediators produce ﬂare
and wheal and induce itch by stimulating sensory nerves
[1]. Oral histamine H1 receptor antagonists (antihistamines)
are the ﬁrst line of treatment for idiopathic urticaria and
other types of urticaria. Second-generation antihistamines
arecommonlyused,becausetheyshowlowercentralnervous
system depression and anticholinergic eﬀects than ﬁrst-
generation drugs. Eﬃcacy, rapidness and duration of action,
and side eﬀects, such as sleepiness and sedation, are known
to vary from drug to drug. Itch aﬀects patient’s quality of
life. Therefore, according to a questionnaire survey, urticaria
patients prefer oral therapy that eﬀectively and promptly
relieves distressing itch [2]. The patients also prefer the drug
with lower side eﬀects.
In this paper, we present a clinical and pharmacolog-
ical study of histamine-induced skin response test using
iontophoresis on two major concerns of urticaria patients,
that is, eﬃcacy and side eﬀects of second-generation anti-
histamines, focusing on suppressive eﬀect, rapidness of
action, and impairment of task performance.
2.MaterialsandMethods
2.1. Subjects. T e nh e a l t h yv o l u n t e e r s( 6m e na n d4w o m e n )
aged 25 to 42 years (mean: 33.50) enrolled in this study.
Subjects were excluded if they had taken any drug that
had antihistamine action or any corticosteroid (oral/topical)
within seven days prior to participation. The study was
approved by the Medical Ethics Committee of Kurume Uni-
versity (Approval no.09028). Verbal and written information
on the study was supplied, and all subjects gave written
consent for study participation.
2.2. Study Design. A double-blinded, crossover, placebo-
controlled protocol was used.
Each subject was given one of four kinds of treat-
ment. We selected 3 second-generation anti-histamines,
olopatadine hydrochloride (olopatadine) 5mg, bepotastine
besilate (bepotastine) 10 mg, and fexofenadine hydrochlo-
ride (fexofenadine) 60mg, which show relatively short
time to maximum concentration (Tmax). These drugs and
a placebo (pantethine) were placed in capsules for oral
administration. Testing for each treatment was separated
by a washout interval of at least 7 days. Subjects received
active or placebo treatment at 9:00a.m. Neither participants2 Dermatology Research and Practice
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Figure 1: Inhibitory eﬀects of anti-histamines on histamine-induced wheal response (a) and ﬂare response (b) after histamine iontophoresis
treatment (n = 10). Results are presented as mean ± SE. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001 (olopatadine versus placebo); ††P < .01
(olopatadine versus bepotastine); #P < .05, ##P < 0.01 (olopatadine versus fexofenadine).
nor physicians had information on the drugs being
tested.
2.3. Histamine-Induced Wheal/Flare Response. Histamine
preparedas0.1%solutionwasinjectedintotheﬂexorsurface
of the forearms (alternating the right and left side) using an
iontophoreser (UI-2060, BS Medical, Tokyo). The electrode
had a tip diameter of 10.0mm. Current was applied for 60s
at 0.1mA. Fifteen minutes after iontophoresis, the wheal
and ﬂare areas were measured by “Image J” software and
expressed as a percentage of the area observed at 0 hour for
all time points.
2.4. Subjective Assessment of Psychomotor Activity. The sub-
jective itch intensity and sleepiness were assessed on a
visual analogue scale (VAS) 10, 13, and 15 minutes after
each iontophoresis, and the mean of the three scores was
considered as itch score for that time point. On VAS of
itch intensity, 0 represented “no itch sensation,” and 100
represented “unbearable itch.” On VAS of sleepiness, 0
represented “not sleepy,” and 100 represented “unbearably
sleepy”.
2.5. Objective Assessment of Psychomotor Activity. Eﬀects on
objective cognitive function were assessed by typing speed
and accuracy for one minute in triplicate at 0, 1, 2, 4 and
8 hours using the type training software “MIKA TYPE”
[3]. The numbers of characters typed and errors made per
minute were recorded in triplicate, and the mean values were
considered as performance score for that time point.
2.6. Statistical Analysis. A l ld a t aw e r ee x p r e s s e da sm e a n±
SE. Statistical analysis of the diﬀerence between diﬀerent
treatment groups was performed by the Tukey’s test (distri-
bution was normal; distribution was tested by Kolmogorov-
Smirnov test) with a signiﬁcance level of 5% (Dr. SPSS II,
SPSS Japan Inc., Tokyo).
3. Results and Discussion
Histamine iontophoresis produced wheal and ﬂare, which
disappeared in about 40 minutes. The wheal and ﬂare areas
induced by the initial iontophoresis at 0 hour were 0.79cm2
and 4.34cm2 in placebo group, 1.04cm2 and 5.13cm2 in
olopatadine group, 0.86cm2 and 5.13cm2 in bepotastine
group, and 0.91cm2 and 5.12cm2 in fexofenadine group,
respectively. All three drugs signiﬁcantly suppressed the
whealresponse,comparedtoplacebo(Figure 1(a)).Olopata-
dine was the only drug that showed a signiﬁcant suppression
of wheal response versus placebo at 0.5 hours and 1
hour and was signiﬁcantly more eﬀective than bepotastine
and fexofenadine. The wheal response at 2 hours was
signiﬁcantly suppressed by olopatadine and bepotastine,
compared to placebo and fexofenadine. After 4 hours, all 3
drugs signiﬁcantly suppressed wheal response, compared to
placebo although olopatadine was signiﬁcantly superior to
fexofenadine.
T h e3d r u g sw e r ea l s oe ﬀective in suppressing ﬂare
response, compared to placebo (Figure 1(b)). Similar to
wheal response, olopatadine was the only drug that showed
signiﬁcant suppression of ﬂare response versus placebo at
0.5 hours and 1 hour and was signiﬁcantly more eﬀective
than fexofenadine at one hour and two hours. After two
hours, all three drugs signiﬁcantly suppressed ﬂare response,
compared to placebo. These ﬁndings indicated the diﬀerence
in suppressing eﬀect among the three drugs; olopatadine
was the fastest and most potent medication, followed by
bepotastineandfexofenadine.PharmacokineticpropertiesofDermatology Research and Practice 3
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Figure 2: Inhibitory eﬀects of anti-histamines on VAS values of
histamine-induced itching sensation after histamine iontophoresis
(n = 10). Results are presented as mean ± SE. ∗P < .05, ∗∗P < .01,
and ∗∗∗P < .001 (olopatadine versus placebo); #P < .05, ##P < .01
(olopatadine versus fexofenadine).
each drug may contribute to this diﬀerence. The rapidness of
action is inﬂuenced by Tmax. Olopatadine has the shortest
Tmax (1.0 hour), followed by bepotastine (1.2 hour) and
fexofenadine (2.2 hours) [4–6]. For the three drugs studied,
the rapidness of suppression of skin responses almost
coincided with Tmax.
The subjective itch intensity was assessed on a VAS. The
itch score at 0 hour before medication was approximately 40
(36.2to46.1).Theplacebogroupshowedthehighestscoreat
0 hour, which tended to gradually decrease. VAS scores at 0.5
hours and 1 hour were decreased only by olopatadine, and
the decrease was signiﬁcant, compared not only to placebo
but also to fexofenadine (Figure 2). After two hours, all
three drugssigniﬁcantly decreased itch scoresversusplacebo.
Decreases seen in olopatadine and bepotastine at two hours
and four hours were signiﬁcantly higher, when compared to
fexofenadine. The signiﬁcantly higher suppression of skin
response and itch by olopatadine was consistent with the
results from previous histamine iontophoresis studies [7, 8].
Olopatadine exhibited a potent noncompetitive antagonism
for the human H1 receptor, which may contribute to the
activity of this drug [9].
Subjective sleepiness was assessed on a VAS. No sig-
niﬁcant diﬀerences were observed for sleepiness up to 8
hours between the drug-treated groups and placebo group
(Figure 3(a)) .H o w e v e r ,V A Ss c o r e sv a r i e dv e r ym u c ha m o n g
subjects. In fact, some subjects, though small in number,
complained of profound sleepiness with every drug, while
other subjects responded diﬀerently to the three drugs. This
ﬁnding supported a large individual diﬀerences in drug-
induced sleepiness, reported by previous publications.
Eﬀects on objective cognitive function were assessed
by typing speed and accuracy. No signiﬁcant diﬀerences
were noted in typing speed (characters typed per minute)
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Figure 3: Evaluation of sedative eﬀects by VAS score for sleepiness
(a), typing speed (b), and typing accuracy (c) (n = 10). (a) VAS
scores: 0 (no drowsiness) to 100 (extensive drowsiness). Resutls are
presented as mean ± SE.4 Dermatology Research and Practice
or accuracy (errors made per minute) between drug-
treated groups and placebo group at any time points
between one hour and eight hours (Figures 3(b) and
3(c)). Second-generation anti-histamines have lower central
nervous system penetrance [10], resulting in reduced central
nervous system eﬀects, compared to the ﬁrst-generation
anti-histamines. This may explain the lack of performance
impairment, an objective indicator of sedation, in our study.
Evaluationofthreesecond-generationanti-histaminesby
means of histamine iontophoresis showed that they were
similar in terms of central nervous system side eﬀects but
were diﬀerent in terms of rapidness of action and eﬃcacy.
Olopatadine was found to be the fastest and most potent
drug. When a rash recurs after remission of acute or chronic
urticaria, an anti-histamine is prescribed for prompt relief
of symptoms. Rapid improvement of the symptoms not only
provides therapeutic beneﬁts to patients but also improves
quality of life by increasing patient’s conﬁdence in alleviating
their anxiety. The data on rapidness of action seen in this
study provide important information that will help us to
choose a suitable anti-histamine for individual urticaria
patients.
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